Knopp Neurosciences, Inc.: Series B $27M

Posted in I - Series B, Q - 4Q08, R - NORTH EAST, X - ALS, X - CNS

Knopp Neurosciences (Pittsburgh, PA) early-stage drug discovery and development company focused on amyotrophic lateral sclerosis and other neurological disorders, closed a $27M Series B financing. Participants include Saturn Partners, Kramer Capital Partners and LaunchCyte.

Dec

2008

BrainsGate, Ltd.: Series C $27.5

Posted in I - Series C, Q - 3Q08, R - INTERNATIONAL, X - CNS

BrainsGate (Israel) development-stage company focused on electrical stimulation for CNS disorders, closed a $27.5M Series C financing. Participants include Johnson & Johnson Development Corp., Agate Medical Investments, Elron Electronic Industries, Pitango Venture Capital, MB Venture Capital and Alice Lab.

Dec

2008

CoLucid Pharmaceuticals: Series B $25M

Posted in I - Series B, Q - 3Q08, R - SOUTH EAST, X - CNS

CoLucid Pharmaceuticals (Raleigh, NC) clinical-stage biotechnology company focusing on therapies for central nervous system disorders, closed a $25M Series B financing. Participants include Pappas Ventures, Domain Associates, Pearl Street Venture Funds and Triathlon Medical Ventures.

Dec

2008

Collegium Pharmaceutical, Inc.: Series D $20M

Posted in I - Series D, Q - 3Q08, R - NORTH EAST, X - CNS, X - Dermatology, X - Respiratory

Collegium Pharmaceutical (Cumberland, RI) commercial-stage specialty pharmaceutical company focused on late-stage development therapeutics for central nervous system, respiratory and skin related disorders, closed a $20M Series D financing. Participants include Frazier Healthcare Ventures.

Dec

2008

Peptimmune, Inc.: Series D $8.9M

Posted in I - Series D, Q - 3Q08, R - NORTH EAST, X - Autoimmune, X - CNS

Peptimmune (Cambridge, MA) clinical-stage biotechnology company developing peptide and peptide-copolymer therapeutics for the treatment of CNS and Autoimmune disorders, closed a $8.9M Series D financing. Participants include New Enterprise Associates, MPM Capital, Hunt Ventures, Boston Medical Investors and Silicon Valley Bank Capital.

Nov

2008

BrainCells, Inc.: Series B $30M

Posted in I - Series B, Q - 1Q08, R - WEST, X - CNS

BrainCells (San Diego, CA) a biopharmaceutical company focused on the development of small molecule therapeutics for diseases of the central nervous system, closed a $30M Series B financing. Participants include MedImmune Ventures, Bay City Capital, Oxford Bioscience Partners, Technology Partners, Pappas Ventures and Neuro Ventures.

Apr

2008

Q Therapeutics, Inc.: Series B $15M

Posted in I - Series B, Q - 1Q08, R - ROCKY MOUNTAIN, X - CNS, X - Stem Cell

Q Therapeutics (Salt Lake City, UT) a development-stage company focused on stem cell therapies for CNS-related disease closed the first tranche of a $15M Series B financing. Participants include vSpring Capital, Invitrogen, Epic Ventures, Toucan Capital, University of Utah Research Foundation, Salt Lake Life Science Angels and Q management.

Next Entries »

to top of page...